Eplerenone for the treatment of cardiovascular disorders

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 7, 2012, Pages 831-838

  Watanabe, Masataka ^a   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

aldosterone receptor blocking agents; cardiovascular disorders; eplerenone; heart failure; mineralocorticoid receptor; treatment

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LOSARTAN; POTASSIUM; SPIRONOLACTONE;

ADD ON THERAPY; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERKALEMIA; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 84865520587     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.64     Document Type: Review

References (50)

1. Tait SA, Tait JF, Coghlan JP. The discovery, isolation and identification of aldosterone: Reflections on emerging regulation and function. Mol. Cell. Endocrinol. 217(1-2), 1-21 (2004). (Pubitemid 38596623)
2. Connell JM, Davies E. The new biology of aldosterone. J. Endocrinol. 186(1), 1-20 (2005). (Pubitemid 41015660)
3. Ferrari P, Krozowski Z. Role of the 11β-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int. 57(4), 1374-1381 (2000). (Pubitemid 30207894)
4. Takeda Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens. Res. 27(11), 781-789 (2004). (Pubitemid 40309445)
5. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc. Res. 35(1), 138-147 (1997). (Pubitemid 27374751)
6. Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 92(2), 175-182 (1995).
7. Brilla CG, Rupp H, Funck R, Maisch B. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur. Heart J. 16(Suppl. O), 107-109 (1995). (Pubitemid 26082358)
8. Roland BL, Krozowski ZS, Funder JW. Glucocorticoid receptor, mineralocorticoid receptors, 11 β-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: In situ studies. Mol. Cell. Endocrinol. 111(1), R1-R7 (1995).
9. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83(6), 1849-1865 (1991).
10. Lösel R, Schultz A, Wehling M. A quick glance at rapid aldosterone action. Mol. Cell. Endocrinol. 217(1-2), 137-141 (2004). (Pubitemid 38596638)
11. MacKenzie SM, Fraser R, Connell JM, Davies E. Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production. J. Renin. Angiotensin. Aldosterone. Syst. 3(4), 214-221 (2002). (Pubitemid 36181991)
12. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283(5), H1802-H1810 (2002). (Pubitemid 35217013)
13. Pitt B, Stier CT Jr, Rajagopalan S. Mineralocorticoid receptor blockade: New insights into the mechanism of action in patients with cardiovascular disease. J. Renin. Angiotensin. Aldosterone. Syst. 4(3), 164-168 (2003). (Pubitemid 37407163)
14. Demers C, McKelvie RS, Yusuf S. The role of digitalis in the treatment of heart failure. Coron. Artery Dis. 10(6), 353-360 (1999). (Pubitemid 29419549)
15. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail. 2(1), 47-54 (1996). (Pubitemid 126666354)
16. Smith PJ, Talbert RL. Sexual dysfunction with antihypertensive and antipsychotic agents. Clin. Pharm. 5(5), 373-384 (1986). (Pubitemid 16050710)
17. Aldridge SA. Drug-induced sexual dysfunction. Clin. Pharm. 1(2), 141-147 (1982). (Pubitemid 12025129)
18. Delyani JA. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int. 57(4), 1408-1411 (2000). (Pubitemid 30207899)
19. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 31(11), 1448-1455 (2003). (Pubitemid 37310335)
20. Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br. J. Pharmacol. 134(1), 224-232 (2001). (Pubitemid 32835486)
21. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev. 10(1), 23-29 (2005). (Pubitemid 40895313)
22. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15(8), 709-716 (2002). (Pubitemid 34804277)
23. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am. Heart J. 160(5), 915-921 (2010).
24. Sadée W, Dagcioglu M, Riegelman S. Fluorometric microassay for spironolactone and its metabolites in biological fluids. J. Pharm. Sci. 61(7), 1126-1129 (1972).
25. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37(5), 1228-1233 (2001). Shows that canrenone has important antiremodeling effects in the postinfarction left ventricular remodeling setting.
26. Parthasarathy HK, Ménard J, White WB et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 29(5), 980-990 (2011).
27. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41(5), 1021-1026 (2003). (Pubitemid 36548598)
28. Williams GH, Burgess E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 93(8), 990-996 (2004). (Pubitemid 38479452)
29. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41(7), 1148-1155 (2003). (Pubitemid 36384902)
30. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin- angiotensin blockade in hypertensive patients. Hypertension 40(2), 117-123 (2002). Describes the efficiency of eplerenone on top of angiotensin-converting enzyme or aldosterone receptor blocker in hypertensive patients. (Pubitemid 34840085)
31. Chapman N, Dobson J, Wilson S et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4), 839-845 (2007). (Pubitemid 351664214)
32. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J. Am. Soc. Hypertens. 2(6), 462-468 (2008).
33. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 108(15), 1831-1838 (2003). (Pubitemid 37296092)
34. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709-717 (1999). First major spironolactone randomized trial in patients with severe heart failure. (Pubitemid 29407370)
35. Pitt B, Remme W, Zannad F et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348(14), 1309-1321 (2003). Efficacy of eplerenone in postmyocardial infarction patients with left ventricular systolic dysfunction. (Pubitemid 36384098)
36. Zannad F, McMurray JJ, Krum H et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364(1), 11-21 (2011). Strongly supports aldosterone blockade for mild systolic dysfunction with congestive heart failure.
37. Khan NU, Movahed A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev. Cardiovasc. Med. 5(2), 71-81 (2004). (Pubitemid 38811465)
38. Boccanelli A, Mureddu GF, Cacciatore G et al.; AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): Final results. Eur. J. Heart Fail. 11(1), 68-76 (2009).
39. Udelson JE, Feldman AM, Greenberg B et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-tomoderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. 3(3), 347-353 (2010).
40. Holland DJ, Prasad SB, Marwick TH. Contribution of exercise echocardiography to the diagnosis of heart failure with preserved ejection fraction (HFpEF). Heart 96(13), 1024-1028 (2010).
41. Soylu A, Temizhan A, Duzenli MA, Sokmen G, Koylu O, Telli HH. The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension. Jpn. Heart J. 45(5), 807-821 (2004). (Pubitemid 40528888)
42. Deuchar GA, McLean D, Hadoke PW et al. 11ß-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 152(1), 236-246 (2011).
43. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145-153 (2000).
44. Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359(9311), 995-1003 (2002). (Pubitemid 34286536)
45. Takeda Y. Role of cardiovascular aldosterone in hypertension. Curr. Med. Chem. Cardiovasc. Hematol. Agents 3(3), 261-266 (2005). (Pubitemid 40974786)
46. Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 17(5), 534-541 (2006).
47. Dixen U, Ravn L, Soeby-Rasmussen C et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 108(1), 35-39 (2007). (Pubitemid 47014348)
48. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc. Health Risk Manag. 7, 353-363 (2011).
49. Gardiner P, Schrode K, Quinlan D et al. Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites. J. Clin. Pharmacol. 29(4), 342-347 (1989). (Pubitemid 19125773)
50. Weinberger MH, White WB, Ruilope LM et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. 150(3), 426-433 (2005). (Pubitemid 41317608)